Management of Naltrexone-Resistant Alcohol Use Disorder

Pharmacotherapy

The American Association for the Study of Liver Diseases (AASLD) recommends adding acamprosate 666 mg three times daily to the existing naltrexone regimen for patients with naltrexone-resistant alcohol use disorder 1, 2
Acamprosate is the optimal add-on medication because it works through a different mechanism (NMDA receptor antagonism) than naltrexone (opioid receptor antagonism), providing complementary effects on alcohol craving and withdrawal symptoms 3, 1
The dose of acamprosate should be 666 mg three times daily (1998 mg total daily) 1, 2
Acamprosate has a critical advantage of no hepatic metabolism and no reported hepatotoxicity, making it safe even if liver disease develops 1, 2
Baclofen 30-60 mg daily is recommended as a second-line addition if acamprosate fails or is not tolerated, with the strongest evidence among medications specifically tested in patients with alcoholic liver disease 1, 2
Gabapentin 600-1800 mg daily and topiramate 75-400 mg daily are third-line options, although neither has been studied specifically in alcoholic liver disease 1, 2

The 2020 AASLD guidelines emphasize that integrating AUD treatment with medical care is the best option for management, and pharmacotherapy alone is insufficient 1, 2
Motivational interviewing (MI) is particularly effective for patients ambivalent about cessation, using the FRAMES model: Feedback, Responsibility, Advice, Menu of options, Empathy, Self-efficacy 1, 2, 7
Cognitive behavioral therapy (CBT) is a first-line behavioral approach that should be combined with pharmacotherapy, focusing on identifying triggers, developing coping strategies, and restructuring thought patterns around alcohol use 6
Contingency management provides tangible rewards for verified abstinence (negative alcohol biomarkers) and may be particularly effective in patients who have not responded to traditional support-based approaches 1, 2

Before continuing or intensifying naltrexone, assess liver function because naltrexone causes hepatocellular injury and undergoes hepatic metabolism 4, 3, 1, 2
If AST/ALT are elevated or cirrhosis is present, discontinue naltrexone and switch to acamprosate or baclofen 1, 2, 6
Anxiety disorders, depression, bipolar disorder, PTSD, and personality disorders are more common in patients with AUD and require concurrent psychiatric treatment 8
Patients who misuse alcohol are at increased risk of being victims and perpetrators of intimate partner violence, which may be a barrier to treatment engagement and requires specific intervention 8